Natural Killer Cells

[Scientific Reports] In cellular models of Philadelphia Chromosome-positive B-ALL, mTOR kinase inhibitors that inhibit both mTOR-complex-1and mTOR-complex-2 enhanced the cytotoxicity of tyrosine kinase inhibitors such as dasatinib.

[Breast Cancer Research and Treatment] The authors examine the role of immune-activating cells, including tumour-infiltrating lymphocytes, and natural killer cells, as well as immune inhibitory cells, including T regulatory cells, and myeloid-derived suppressor cells in the breast cancer tumour microenvironment.

[Endocrine-Related Cancer] Investigators discuss the diverse roles of MUC4 in tumor progression and metastasis, and propose that intervening in MUC4 intercellular interactions with binding partners on blood-borne aggregating cells could potentially thwart breast cancer metastatic efficiency.

[Exacis Biotherapeutics, Inc. (PR Newswire, Inc.)] Exacis Biotherapeutics, Inc. announced initiation of a strategic partnership with Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM) for specialty manufacturing services related to the development of Exacis' innovative, iPSC-derived mRNA-engineered natural killer cell products to treat cancer.

[EMBO Molecular Medicine] Scientists described a non-viral lipid nanoparticle-based delivery system that encapsulated small interfering RNAs to gene silence the key intrinsic inhibitory NK cell molecules, SHP-1, Cbl-b, and c-Cbl.

[Scientific Reports] To study Hsp70 forms released from cells scientists employed the assay consisting of two affinity chromatography methods. Hsp70 content in culture medium and extracellular vesicles was measured with the aid of ELISA.